Body Pharm Tirzepatide 30 Pen

Each unit contains :

1x Tirzepatide 30mg muti dosage pen

8x Pen needles

1x Guidelines Insert


BP Tirzepatide 30 Pen (30mg Tirzepatide), this medication is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes

Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, recently developed and finally approved in May 2022 by the Food and Drug Administration for the treatment of T2DM as an adjunct to diet and exercise. In subjects with T2DM, dual GIP and GLP-1 receptor agonism with tirzepatide, compared to single GLP-1 receptor agonism with semaglutide, produced significantly more significant improvements in total insulin secretion rate and insulin sensitivity, reflecting a significant improvement compared to semaglutide.

Similar effects were also documented in another mechanistic trial comparing tirzepatide with dulaglutide, another GLP-1 receptor agonist, suggesting that dual receptor agonism might indeed be responsible for improving insulin sensitivity, especially since the observed effect was shown to be only partially attributable to weight loss. Furthermore, the effect of tirzepatide on delayed gastric emptying is comparable to that induced by single GLP-1 receptor agonism.

Benefits of Tirzepatide:
Blood Sugar Control: Tirzepatide mimics GLP-1 and GLI, regulating blood sugar levels. It prompts insulin release when blood sugar is high and reduces glucagon production, which raises blood sugar.
Weight Management: Tirzepatide promotes weight loss by increasing satiety, reducing food intake, and aiding in weight reduction.
Cardiovascular Benefits: Some studies suggest Tirzepatide may reduce the risk of heart-related complications in type 2 diabetes.